Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Tandem Diabetes Care (TNDM) over the last 13 years, with Q3 2025 value amounting to $3.2 million.

  • Tandem Diabetes Care's Asset Writedowns and Impairment fell 1145.57% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year increase of 737.24%. This contributed to the annual value of $10.0 million for FY2024, which is 8012.64% up from last year.
  • Per Tandem Diabetes Care's latest filing, its Asset Writedowns and Impairment stood at $3.2 million for Q3 2025, which was down 1145.57% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, Tandem Diabetes Care's Asset Writedowns and Impairment peaked at $3.6 million during Q3 2024, and registered a low of $143000.0 during Q1 2021.
  • Over the past 5 years, Tandem Diabetes Care's median Asset Writedowns and Impairment value was $1.4 million (recorded in 2023), while the average stood at $1.5 million.
  • As far as peak fluctuations go, Tandem Diabetes Care's Asset Writedowns and Impairment plummeted by 8341.07% in 2021, and later surged by 49160.84% in 2022.
  • Over the past 5 years, Tandem Diabetes Care's Asset Writedowns and Impairment (Quarter) stood at $871000.0 in 2021, then surged by 109.76% to $1.8 million in 2022, then decreased by 19.32% to $1.5 million in 2023, then soared by 81.61% to $2.7 million in 2024, then rose by 18.38% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $2.1 million for Q2 2025, and $1.4 million during Q1 2025.